Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: The esport study

ObjectiveTo compare the efficacy and safety of the angiotensin II antagonist olmesartan medoxomil (O) and the ACE inhibitor ramipril (R) in elderly patients with essential arterial hypertension.MethodsAfter a 2-week placebo wash-out 1102 treated or untreated elderly hypertensive patients aged 65–89